Estimation of the effect of body weight on the development of osteoarthritis based on cumulative stresses in cartilage : data from the osteoarthritis initiative
|Author:||Klets, Olesya1,2; Mononen, Mika E.3; Liukkonen, Mimmi K.3;|
1Research Unit of Medical Imaging, Physics and Technology, University of Oulu, Oulu, Finland
2Medical Research Center Oulu, University of Oulu, Oulu, Finland
3Department of Applied Physics, University of Eastern Finland, Kuopio, Finland
4Department of Diagnostic Radiology, Oulu University Hospital, Oulu, Finland
5Diagnostic Imaging Centre, Kuopio University Hospital, Kuopio, Finland
|Online Access:||PDF Full Text (PDF, 2.1 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019111438105
|Publish Date:|| 2019-11-14
Evaluation of the subject-specific biomechanical effects of obesity on the progression of OA is challenging. The aim of this study was to create 3D MRI-based finite element models of the knee joints of seven obese subjects, who had developed OA at 4-year follow-up, and of seven normal weight subjects, who had not developed OA at 4-year follow-up, to test the sensitivity of cumulative maximum principal stresses in cartilage in quantitative risk evaluation of the initiation and progression of knee OA. Volumes of elements with cumulative stresses over 5 MPa in tibial cartilage were significantly (p < 0.05) larger in obese subjects as compared to normal weight subjects. Locations of high peak cumulative stresses at the baseline in most of the obese subjects showed a good agreement with the locations of the cartilage loss and MRI scoring at follow-up. Simulated weight loss (to body mass index 24 kg/m²) in obese subjects led to significant reduction of the highest cumulative stresses in tibial and femoral cartilages. The modeling results suggest that an analysis of cumulative stresses could be used to evaluate subject-specific effects of obesity and weight loss on cartilage responses and potential risks for the progression of knee OA.
Annals of biomedical engineering
|Pages:||334 - 344|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
217 Medical engineering
The research leading to results in the manuscript has received funding from the University of Oulu (strategic funding), the Medical Research Center of University of Oulu and Oulu University Hospital, Academy of Finland (Grants 286526, 268378 and 305138), Sigrid Juselius Foundation, and Finnish Cultural Foundation (North Savo regional fund, Grant No. 65142194). The OAI is a public–private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health.
|Academy of Finland Grant Number:||
286526 (Academy of Finland Funding decision)
268378 (Academy of Finland Funding decision)
305138 (Academy of Finland Funding decision)
© Biomedical Engineering Society 2017. This is a post-peer-review, pre-copyedit version of an article published in Annals of Biomedical Engineering. The final authenticated version is available online at: https://doi.org/10.1007/s10439-017-1974-6.